Comparison of Metformin and Metformin Plus Liraglutide for Treating Metabolic Syndrome in Patients with Polycystic Ovarian Syndrome (PCOS)
Abstract
Background: This study compares the effectiveness of metformin (MET) monotherapy versus a combination of MET and liraglutide (LIRA) in managing metabolic syndrome in overweight women with polycystic ovary syndrome (PCOS), focusing on weight reduction and body mass index (BMI). Methods: A prospective cohort was conducted at Lady Dufferin Hospital, Karachi from April 2024 to Oct 2024, involving 70 women aged 18–40 years, diagnosed with PCOS based on Rotterdam criteria, and having a BMI ≥ 27.5 kg/m². Participants were randomly assigned into two groups: Group A received MET (1500 mg/day), and Group B received MET (1500 mg/day) plus LIRA (1.2 mg/day) for 12 weeks. Baseline and post-treatment outcomes, including weight, BMI, waist circumference, and lipid profiles, were analyzed. Results: Both treatment regimens significantly improved metabolic parameters. Group B demonstrated superior results with an average weight loss of 10.30 ± 1.30 kg and BMI reduction of 3.72 ± 0.67, compared to Group A’s weight loss of 5.99 ± 2.87 kg and BMI reduction of 2.24 ± 1.07 (p < 0.001). Improvements in triglyceride levels, HDL cholesterol, and waist circumference were more pronounced in Group B. However, no significant changes in hypertension parameters were observed in either group. Conclusion: The combination of MET and LIRA is more effective than MET monotherapy in managing metabolic syndrome in overweight PCOS patients. This dual therapy offers enhanced metabolic benefits, potentially improving…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.